Skip to main content
Premium Trial:

Request an Annual Quote

Aptus Genomics Appoints Former Shire Co-founder President

NEW YORK, Sept. 28 - Aptus Genomics, a biotech company that focuses on G-protein coupled receptor genes, has appointed Krystyna Belendiuk as president, the company said on Friday. 

"I am very pleased to have someone with Krystyna's knowledge and experience join the Aptus management team," Kevin Chance, founder and CEO of Aptus, said in a statement. 

Before joining Aptus, Belendiuk was co-founder, director, and senior vice president of Pharmavene, now known as Shire Laboratories.

Aptus, which in June moved its headquarters to Gaithersburg, Md., from Rockville, Md., reported in May that it raised $6.2 million in a round of financing. 

The company, founded in June 2000, is currently completing gene collection and will move to high-throughput functional assays and screening to be used for in-house drug discovery development and future partnership collaborations, Chance told GenomeWeb in May.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.